Compare
Phathom Pharmaceuticals, Inc. vs Cryoport, Inc. vs Syndax Pharmaceuticals Inc vs Lifevantage Corp
| Latest fiscal year | Phathom Pharmaceuticals, Inc. PHAT | Cryoport, Inc. CYRX | Syndax Pharmaceuticals Inc SNDX | Lifevantage Corp LFVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $175.11M | $176.18M | $172.35M | $182.59M |
| Revenue growth (YoY) | +216.9% | +12.4% | +627.8% | -20.1% |
| Gross margin | 87.1% | 47.1% | n/a | 77.6% |
| Operating margin | -91.4% | -20.9% | -158.4% | 3.3% |
| Net margin | -126.3% | 44.4% | -165.6% | 2.8% |
| Net income | -$221.25M | $78.30M | -$285.42M | $5.07M |
| EPS (Diluted) | -$3.03 | $1.40 | -$3.29 | $0.40 |
| Operating cash flow | -$166.78M | -$8.58M | -$322.98M | $10.24M |
| Free cash flow | -$167.00M | -$25.02M | -$323.17M | $6.67M |
| Cash & equivalents | $129.97M | $250.49M | $134.93M | n/a |
| Total assets | $259.15M | $764.99M | $529.71M | $62.11M |
| Total liabilities | $697.32M | $262.35M | $465.08M | $28.52M |
| Shareholders' equity | -$438.17M | $502.64M | $64.63M | $33.59M |
| Return on year-end equity | n/a | 15.6% | -441.6% | 15.1% |
| Shares outstanding | 71.42M | 49.85M | 87.41M | 12.52M |
Revenue, most recent five fiscal years
| Fiscal year | Phathom Pharmaceuticals, Inc. | Cryoport, Inc. | Syndax Pharmaceuticals Inc | Lifevantage Corp |
|---|---|---|---|---|
| Latest | $175.11M Ended 2025-12-31 | $176.18M Ended 2025-12-31 | $172.35M Ended 2025-12-31 | $182.59M Ended 2026-06-30 |
| 1 year earlier | $55.25M Ended 2024-12-31 | $156.77M Ended 2024-12-31 | $23.68M Ended 2024-12-31 | $228.53M Ended 2025-06-30 |
| 2 years earlier | $682.0K Ended 2023-12-31 | $168.66M Ended 2023-12-31 | $0 Ended 2023-12-31 | $200.16M Ended 2024-06-30 |
| 3 years earlier | $0 Ended 2022-12-31 | $237.28M Ended 2022-12-31 | $0 Ended 2022-12-31 | $213.40M Ended 2023-06-30 |
| 4 years earlier | n/a | $222.61M Ended 2021-12-31 | $139.71M Ended 2021-12-31 | $206.36M Ended 2022-06-30 |